[Treated cases of retinopathy of prematurity in Germany : 5-year data from the Retina.net ROP registry].
CONCLUSION: The data in this analysis represent about 10-15% of treated infants in Germany. The results provide evidence for an increasing use of anti-VEGF agents for ROP. The data reflect a selection bias for anti-VEGF treatment in eyes with a more aggressive disease. This needs to be considered when interpreting data such as disease recurrence rates. The risk for late recurrences after anti-VEGF treatment is of particular clinical significance.
PMID: 29637302 [PubMed - as supplied by publisher]
Source: Der Ophthalmologe - Category: Opthalmology Authors: Walz JM, Bemme S, Reichl S, Akman S, Breuß H, Süsskind D, Glitz B, Müller VC, Wagenfeld L, Gabel-Pfisterer A, Aisenbrey S, Engelmann K, Koutsonas A, Krohne TU, Stahl A, Retina.net ROP-Register-Studiengruppe Tags: Ophthalmologe Source Type: research
More News: Avastin | Blindness | Eyes | Germany Health | Lucentis | Opthalmology | Ranibizumab Injection